Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

The goal of this project is to see if two new potential treatments (defactinib and the combination tablet of decitabine/cedazuridine) can safely be combined to improve outcomes in people with high-risk myelodysplastic syndrome (MDS), certain forms of Acute Myeloid Leukaemia (AML), and Chronic Myelomonocytic Leukaemia (CMML). Decitabine/cedazuridine is approved for use by the Australian Therapeutics Goods Administration (TGA) as treatment for MDS. Defactinib is an experimental treatment. This means it is not an approved treatment for MDS in Australia. So far it has been given to over 625 patien

Trial Details

NCT ID
NCT05636514
Phase
PHASE1
Sponsor
Clinical Hub for Interventional Research (CHOIR)
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
  • Defactinib
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Westmead, New South Wales, Australia|-33.80383,150.98768

Key Eligibility Criteria

  • Participants must meet all of the following criteria at the time of screening:
  • Age ≥ 18 years
  • Documented diagnosis of:
  • Myelodysplastic syndrome (MDS) classified as intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS), or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →